This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Bibliografia
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):939–952
Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191
Amato MP, Ponziani G (1999) Quantification of impairment in MS: discussion of the scales in use. Mult Scler 5(4):216–219
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
Grimaud J, Auray JP, Collectif sep des villes et sep des champs (2004) Quality of life and economic cost of multiple sclerosis. Rev Neurol 160(1):23–34
The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661
Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscolar interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39(3):285–294
PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498–1504
Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276
European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497
Hartung HP, Gonsette R, Konig N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025
Goodin DS, Frohman EM, Garmany GP jr et al (2002) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178
Panitch H, Goodin DS, Francis G et al (2002) Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59(10):1496–1506
Durelli L, Verdun E, Barbero P et al (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta 1-a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316):1453–1460
Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904
Comi G, Filippi M, Barkhof F et al (2001) Early treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582
Filippini G, Munari L, Incorvaia B et al (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361(9357):545–552
Rights and permissions
Copyright information
© 2005 Springer-Verlag Italia
About this chapter
Cite this chapter
Amato, M., Zipoli, V. (2005). La sclerosi multipla. In: Costi sociali e aspetti farmacoeconomici. Aspetti psico-sociali della sclerosi multipla, vol 4. Springer, Milano. https://doi.org/10.1007/88-470-0401-2_1
Download citation
DOI: https://doi.org/10.1007/88-470-0401-2_1
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0327-9
Online ISBN: 978-88-470-0401-6
eBook Packages: MedicineMedicine (R0)